Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,193 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ADD Clear all
Not listed Phase 2Phase 3 Interventional

BioFreedom US IDE Feasibility Trial

NCT02131142
View directory record Official record
Conditions
Ischemic Heart Disease, Stable Angina, Unstable Angina, Silent Ischemia
Interventions
BioFreedom drug coated coronary stent
Device
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Jul 22, 2026, 11:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

BABE(Body Appreciation and Better Eating), Add Some Self-compassion

NCT05786560
View directory record Official record
Conditions
Body Image, Eating Behavior, Binge Eating, Nutrition, Healthy, Disordered Eating
Interventions
BABE (Body Appreciation and Better Eating)
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 11:03 AM EDT
Recruiting Phase 2 Interventional

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420
View directory record Official record
Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
Interventions
Efgartigimod IV, Empasiprubart IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Carlsbad, California • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

NCT00973024
View directory record Official record
Conditions
Low Back Pain, Low Back Pain, Recurrent
Interventions
JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg, JNJ-42160443 10 mg, Matching Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Reinforcing Mechanisms of Smoking in Adult ADHD

NCT00573859
View directory record Official record
Conditions
ADHD
Interventions
ADHD medication, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

NCT02228772
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia
Interventions
MLN 9708, Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
51 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Food Additives Effects on EEG Profiles in College Students With ADHD

NCT03342469
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Artificial Food Coloring, Placebo
Other
Lead sponsor
American University
Other
Eligibility
18 Years to 24 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Zero Calorie Drink Products

NCT00525694
View directory record Official record
Conditions
Obesity
Interventions
Glucose tolerance test, glucose tolerance test solution, Diet Coke, Coke Zero
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 22, 2026, 11:03 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]

NCT06713382
View directory record Official record
Conditions
Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
Interventions
Pleural Saline Irrigation
Combination Product
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Testing "SupporT for ADHD and Related Treatment" (START) for Families of Children With ADHD

NCT05796427
View directory record Official record
Conditions
ADHD
Interventions
SupporT for ADHD and Related Treatment
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Evaluating Two Multifocal Daily Disposable Contact Lenses

NCT05579886
View directory record Official record
Conditions
Presbyopia
Interventions
Control Lens, Test Lens
Device
Lead sponsor
CooperVision, Inc.
Industry
Eligibility
42 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Ocoee, Florida • Pittsburg, Kansas • Vestal, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

NCT00312494
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

d13C Added Sugar Intake Biomarker: Determining Validity in Children

NCT02455388
View directory record Official record
Conditions
Validation Studies
Interventions
High added sugar diet, Low added sugar diet
Dietary Supplement
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
6 Years to 18 Years
Enrollment
370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 22, 2026, 11:03 AM EDT
Completed No phase listed Observational Results available

Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)

NCT02073331
View directory record Official record
Conditions
Coronary Disease
Interventions
Not listed
Lead sponsor
Elutia Inc.
Industry
Eligibility
Not listed
Enrollment
1,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Jul 22, 2026, 11:03 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional Results available

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

NCT04871529
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00190931
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD

NCT00989950
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, INSOMNIA
Interventions
Daytrana
Drug
Lead sponsor
Cox Health Systems
Other
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Jul 22, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Added Sugar Intake, Sweet Taste Phenotypes and Biomarkers

NCT05047588
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
3 Years to 70 Years
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

NCT00294710
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

NCT00892723
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Jul 22, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jul 22, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

NCT03103750
View directory record Official record
Conditions
ADHD
Interventions
Magnetic Resonance Imaging (MRI), PHNO, calcitriol, Placebo oral capsule, high-resolution research tomography, Dextro Amphetamine
Procedure · Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Jul 22, 2026, 11:03 AM EDT